Eli L. Diamond

12.1k total citations · 2 hit papers
115 papers, 3.8k citations indexed

About

Eli L. Diamond is a scholar working on Physiology, Immunology and Molecular Biology. According to data from OpenAlex, Eli L. Diamond has authored 115 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Physiology, 31 papers in Immunology and 25 papers in Molecular Biology. Recurrent topics in Eli L. Diamond's work include Histiocytic Disorders and Treatments (66 papers), Mast cells and histamine (23 papers) and Palliative Care and End-of-Life Issues (19 papers). Eli L. Diamond is often cited by papers focused on Histiocytic Disorders and Treatments (66 papers), Mast cells and histamine (23 papers) and Palliative Care and End-of-Life Issues (19 papers). Eli L. Diamond collaborates with scholars based in United States, France and Israel. Eli L. Diamond's co-authors include Omar Abdel‐Wahab, Benjamin H. Durham, Lauren B. Marangell, Marlene P. Freeman, Andrew L. Stoll, W. Emanuel Severus, Holly A. Zboyan, Reisa A. Sperling, Kenneth L. McClain and David M. Hyman and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Eli L. Diamond

103 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Omega 3 Fatty Acids in Bipolar Disorder

1999 584 citations Eli L. Diamond et al. profile →
Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease

2018 313 citations Jean‐François Emile, Benjamin H. Durham et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eli L. Diamond United States	29	1.8k	720	660	563	503	115	3.8k
Izumi Kawachi Japan	18	639 0.3×	262 0.4×	591 0.9×	424 0.8×	349 0.7×	81	5.3k
Maurizio Leone Italy	36	345 0.2×	436 0.6×	688 1.0×	174 0.3×	257 0.5×	148	4.2k
Gil I. Wolfe United States	37	531 0.3×	798 1.1×	214 0.3×	152 0.3×	461 0.9×	134	5.6k
Markku Ryynänen Finland	38	897 0.5×	255 0.4×	353 0.5×	56 0.1×	316 0.6×	132	4.4k
Giulio Disanto United Kingdom	35	334 0.2×	200 0.3×	3.4k 5.1×	767 1.4×	556 1.1×	93	5.4k
Maura Pugliatti Italy	39	264 0.1×	174 0.2×	2.2k 3.4×	323 0.6×	552 1.1×	157	4.3k
Oluf Andersen Sweden	39	642 0.4×	211 0.3×	2.6k 3.9×	782 1.4×	912 1.8×	135	5.9k
Pieter A. van Doorn Netherlands	50	2.9k 1.6×	84 0.1×	495 0.8×	199 0.4×	1.8k 3.5×	197	9.1k
Ilaria Casetta Italy	38	230 0.1×	120 0.2×	1.1k 1.7×	269 0.5×	331 0.7×	149	3.8k
Raúl N. Mandler United States	25	245 0.1×	301 0.4×	1.5k 2.2×	260 0.5×	485 1.0×	77	3.4k

Countries citing papers authored by Eli L. Diamond

Since Specialization

Citations

This map shows the geographic impact of Eli L. Diamond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eli L. Diamond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eli L. Diamond more than expected).

Fields of papers citing papers by Eli L. Diamond

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eli L. Diamond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eli L. Diamond. The network helps show where Eli L. Diamond may publish in the future.

Co-authorship network of co-authors of Eli L. Diamond

This figure shows the co-authorship network connecting the top 25 collaborators of Eli L. Diamond. A scholar is included among the top collaborators of Eli L. Diamond based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eli L. Diamond. Eli L. Diamond is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Halteren, Astrid G. S. van, Paul G. Kemps, Yanling Xiao, et al.. (2025). Driver mutations in myeloid and lymphoid cells point to multipotent progenitor origin of diverse histiocytic neoplasms. PubMed. 2(2). 100074–100074. 1 indexed citations

Francis, Jasmine H., et al.. (2024). Subfoveal Choroidal Thickness in Patients with Histiocytosis and Multimodal Imaging Features of Choroidal Infiltrates. Ophthalmology Retina. 9(6). 580–588.

Salmon‐Divon, Mali, Ofer Shpilberg, Elimelech Okon, et al.. (2024). The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasms. Leukemia. 39(2). 516–519. 2 indexed citations

Applebaum, Allison J., Elizabeth Schofield, Rebecca Gebert, et al.. (2024). Effects of a communication skills training program to improve capacity to engage in advance care planning in caregivers of patients with malignant gliomas. PubMed. 6(3).

Diamond, Eli L., et al.. (2024). Erdheim-Chester Disease Masquerading as CLIPPERS. Neurology Neuroimmunology & Neuroinflammation. 11(5). e200294–e200294. 1 indexed citations

Makras, Polyzois, Dana Erickson, Caroline Davidge‐Pitts, et al.. (2024). Approach to the Patient: From Endocrinopathy to the Diagnosis of a Histiocytic Disorder. The Journal of Clinical Endocrinology & Metabolism. 110(6). 1756–1766. 3 indexed citations

Imber, Brandon S., Rupesh Kotecha, Rosemary J. Young, et al.. (2024). Multi-Center Phase I Study of Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases (BM) or Leptomeningeal Metastases (LM) Harboring PI3K Pathway Mutations. International Journal of Radiation Oncology*Biology*Physics. 120(2). S193–S193.

Riancho, José A., José L. Hernández, Carmen González‐Vela, et al.. (2023). Erdheim–Chester Disease Due to a Novel Internal Duplication of NRAS: Response to Targeted Therapy with Cobimetinib. International Journal of Molecular Sciences. 24(20). 15467–15467. 1 indexed citations

Emile, Jean‐François, Zofia Hélias‐Rodzewicz, Benjamin H. Durham, et al.. (2023). Histiocytic neoplasm subtypes differ in their MAP2K1 mutational type. Blood Advances. 7(23). 7254–7257. 4 indexed citations

10.

Francis, Jasmine H., William Foulsham, James J. Harding, et al.. (2023). Mitogen-Activated Pathway Kinase Inhibitor-Associated Retinopathy: Do Features Differ with Upstream versus Downstream Inhibition?. Ocular Oncology and Pathology. 9(1-2). 25–31. 1 indexed citations

11.

Coffee, Elizabeth, Thomas Kaley, Eli L. Diamond, Alexandra Miller, & Lauren Schaff. (2022). BRAFV600E-mutant glioblastoma responds to combination BRAF/MEK inhibition with encorafenib and binimetinib (P5-9.007). Neurology. 98(18_supplement).

12.

Francis, Jasmine H., James J. Harding, Eli L. Diamond, et al.. (2021). Clinical and Morphologic Characteristics of Extracellular Signal-Regulated Kinase Inhibitor-Associated Retinopathy. Ophthalmology Retina. 5(12). 1187–1195. 7 indexed citations

13.

Subbiah, Vivek, Igor Puzanov, Jean‐Yves Blay, et al.. (2020). Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers. Cancer Discovery. 10(5). 657–663. 86 indexed citations

14.

King, Amber C., et al.. (2019). Cobimetinib‐induced “dropped head syndrome” and subsequent disease management in an Erdheim‐Chester patient. SHILAP Revista de lepidopterología. 7(10). 1989–1993. 7 indexed citations

15.

Zarnegar, Sara, Benjamin H. Durham, Pallavi Khattar, et al.. (2017). Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis. Pediatric Blood & Cancer. 65(1). 17 indexed citations

16.

Diamond, Eli L., Benjamin H. Durham, Ahmet Doǧan, et al.. (2017). Phase 2 Trial of Single-Agent Cobimetinib for Adults with BRAF V600-Mutant and Wild-Type Histiocytic Disorders. Blood. 130. 257–257. 3 indexed citations

17.

Diamond, Eli L., Katherine S. Panageas, Allison J. Applebaum, et al.. (2016). Frequency and Predictors of Acute Hospitalization Before Death in Patients With Glioblastoma. Journal of Pain and Symptom Management. 53(2). 257–264. 25 indexed citations

18.

Diamond, Eli L., David Russell, Maria Kryza‐Lacombe, et al.. (2015). Rates and risks for late referral to hospice in patients with primary malignant brain tumors. Neuro-Oncology. 18(1). 78–86. 57 indexed citations

19.

Hyman, David M., Eli L. Diamond, Cecile Rose T. Vibat, et al.. (2014). Prospective Blinded Study of BRAF V600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders. Cancer Discovery. 5(1). 64–71. 84 indexed citations

20.

Diamond, Eli L., et al.. (1989). Decision-Making Ability and Advance Directive Preferences in Nursing Home Patients and Proxies. The Gerontologist. 29(5). 622–626. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact